Jade Biosciences (JBIO) Non Operating Income (2021 - 2026)

Jade Biosciences (JBIO) has 7 years of Non Operating Income data on file, last reported at $3.1 million in Q1 2026.

• Quarterly Non Operating Income rose 120.92% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (up 116.64% YoY) and the FY2025 annual result came in at -$13.8 million, down 374.94% from the prior year.
• Non Operating Income was little changed at $3.1 million in Q1 2026, from $3.1 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $3.1 million in Q4 2025 to a low of -$14.8 million in Q1 2025.
• A 5-year average of -$656705.9 and a median of $1.1 million in 2023 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2022 — Non Operating Income soared 11400.0% — and 2025, when it slumped 1132.47%.
• Tracing JBIO's Non Operating Income over 5 years: stood at $934000.0 in 2022, then surged by 82.98% to $1.7 million in 2023, then plunged by 769.46% to -$11.4 million in 2024, then jumped by 127.14% to $3.1 million in 2025, then declined by 0.39% to $3.1 million in 2026.
• The last three Non Operating Income figures came in at $3.1 million (Q1 2026), $3.1 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.